Injection Site Reaction

There have been some reports of necrosis at the injection site following receipt of the 23-valent pneumococcal vaccine, but the vaccine’s overall benefit-risk balance “remains favorable,” researchers wrote in JAMA Internal Medicine.

WASHINGTON — Treatment with vupanorsen, a novel antisense oligonucleotide targeting hepatic ANGPTL3, achieved modest reductions in non-HDL at 24 weeks at all doses studied, according to results of the TRANSLATE-TIMI 70 trial.

Cutaneous reactions to the mRNA-based COVID-19 vaccines were mostly minor and self-limited and should not discourage individuals from receiving a vaccine, according to a study.

The FDA has extended approval for ixekizumab injection 80 mg/mL to treat adults with ankylosing spondylitis – or radiographic axial spondyloarthritis - according to an Eli Lilly press release.